In vitro studies found that primary CML patient cells treated with asciminib and ponatinib demonstrated decreased BCR::ABL1 activity and colony formation compared with asciminib monotherapy [47]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.